Robert (Bob) Grant is a Senior Investigator at the Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of California San Francisco. Dr. Grant has 28 years of experience with HIV/AIDS research and clinical care, including 11 years of experience with studies of post and pre-exposure prophylaxis. He is the protocol chair of the iPrEx trial, called “Chemoprophylaxis for HIV Prevention in Men,” which was funded by the NIH and the Bill and Melinda Gates Foundation. He is also the protocol chair for HPTN 067, called the ADAPT study (Alternative Dosing to Augment PrEP Tablet use). He is a co-investigator for the FEM-PREP trial, the CDC sponsored safety study of PrEP safety in US MSM, and the West African PrEP study. Dr. Grant serves on the PrEP trialists working group, and acts as an advisor to the WHO, UNAIDS, CDC, and Gilead regarding the prevention use of antiretroviral therapy. Dr. Grant's laboratory is also interested in HIV-1 superinfection, drug resistance, and mutagenesis.